case_images: PMC11739760_01
case_images: Platelet counts throughout chemotherapy treatment. (A) Clinical Case 1, (B) Clinical Case 2, (C) Clinical Case 3, (D) Clinical Case 4, (E) Clinical Case 5, (F) Clinical Case 6. 5-FU, 5-fluorouracil; AVA, avatrombopag; BEV, bevacizumab; C, cycle; Carbo, carboplatin; Cis, cisplatin; Durva, durvalumab; ELT, eltrombopag; FOLFOX, 5-fluorouracil and oxaliplatin + leucovorin; Gem, gemcitabine; IRI, irinotecan; q.d., once daily; q.o.d., every other day; red, reduced; TRA, trastuzumab.
case_images: BJH-206-272-g001.jpg
case_images: PMC11739760_05_BJH-206-272-g001.jpg
case_images: bjh19797-fig-0001
case_images: Persistent thrombocytopenia (PC 71 x 109/L) developed and AVA 20 mg QD was initiated on D1 of the enfortumab vedotin dose reduction to avoid treatment interruption and any further decrease in dose (Figure 1F).
case_images: PMC11739760_02
case_images: Platelet counts throughout chemotherapy treatment. (A) Clinical Case 1, (B) Clinical Case 2, (C) Clinical Case 3, (D) Clinical Case 4, (E) Clinical Case 5, (F) Clinical Case 6. 5-FU, 5-fluorouracil; AVA, avatrombopag; BEV, bevacizumab; C, cycle; Carbo, carboplatin; Cis, cisplatin; Durva, durvalumab; ELT, eltrombopag; FOLFOX, 5-fluorouracil and oxaliplatin + leucovorin; Gem, gemcitabine; IRI, irinotecan; q.d., once daily; q.o.d., every other day; red, reduced; TRA, trastuzumab.
case_images: BJH-206-272-g001.jpg
case_images: PMC11739760_05_BJH-206-272-g001.jpg
case_images: bjh19797-fig-0001
case_images: Persistent thrombocytopenia (PC 71 x 109/L) developed and AVA 20 mg QD was initiated on D1 of the enfortumab vedotin dose reduction to avoid treatment interruption and any further decrease in dose (Figure 1F).
case_images: PMC11739760_03
case_images: Platelet counts throughout chemotherapy treatment. (A) Clinical Case 1, (B) Clinical Case 2, (C) Clinical Case 3, (D) Clinical Case 4, (E) Clinical Case 5, (F) Clinical Case 6. 5-FU, 5-fluorouracil; AVA, avatrombopag; BEV, bevacizumab; C, cycle; Carbo, carboplatin; Cis, cisplatin; Durva, durvalumab; ELT, eltrombopag; FOLFOX, 5-fluorouracil and oxaliplatin + leucovorin; Gem, gemcitabine; IRI, irinotecan; q.d., once daily; q.o.d., every other day; red, reduced; TRA, trastuzumab.
case_images: BJH-206-272-g001.jpg
case_images: PMC11739760_05_BJH-206-272-g001.jpg
case_images: bjh19797-fig-0001
case_images: Persistent thrombocytopenia (PC 71 x 109/L) developed and AVA 20 mg QD was initiated on D1 of the enfortumab vedotin dose reduction to avoid treatment interruption and any further decrease in dose (Figure 1F).
case_images: PMC11739760_04
case_images: Platelet counts throughout chemotherapy treatment. (A) Clinical Case 1, (B) Clinical Case 2, (C) Clinical Case 3, (D) Clinical Case 4, (E) Clinical Case 5, (F) Clinical Case 6. 5-FU, 5-fluorouracil; AVA, avatrombopag; BEV, bevacizumab; C, cycle; Carbo, carboplatin; Cis, cisplatin; Durva, durvalumab; ELT, eltrombopag; FOLFOX, 5-fluorouracil and oxaliplatin + leucovorin; Gem, gemcitabine; IRI, irinotecan; q.d., once daily; q.o.d., every other day; red, reduced; TRA, trastuzumab.
case_images: BJH-206-272-g001.jpg
case_images: PMC11739760_05_BJH-206-272-g001.jpg
case_images: bjh19797-fig-0001
case_images: Persistent thrombocytopenia (PC 71 x 109/L) developed and AVA 20 mg QD was initiated on D1 of the enfortumab vedotin dose reduction to avoid treatment interruption and any further decrease in dose (Figure 1F).
case_images: PMC11739760_05
case_images: Platelet counts throughout chemotherapy treatment. (A) Clinical Case 1, (B) Clinical Case 2, (C) Clinical Case 3, (D) Clinical Case 4, (E) Clinical Case 5, (F) Clinical Case 6. 5-FU, 5-fluorouracil; AVA, avatrombopag; BEV, bevacizumab; C, cycle; Carbo, carboplatin; Cis, cisplatin; Durva, durvalumab; ELT, eltrombopag; FOLFOX, 5-fluorouracil and oxaliplatin + leucovorin; Gem, gemcitabine; IRI, irinotecan; q.d., once daily; q.o.d., every other day; red, reduced; TRA, trastuzumab.
case_images: BJH-206-272-g001.jpg
case_images: PMC11739760_05_BJH-206-272-g001.jpg
case_images: bjh19797-fig-0001
case_images: Persistent thrombocytopenia (PC 71 x 109/L) developed and AVA 20 mg QD was initiated on D1 of the enfortumab vedotin dose reduction to avoid treatment interruption and any further decrease in dose (Figure 1F).